GamaMabs Pharma Overview
- Year Founded
-
2013
- Status
-
Private
- Employees
-
7
- Latest Deal Type
-
2ndary - Private
- Investors
-
9
GamaMabs Pharma General Information
Description
Developer of optimized therapeutic antibodies designed for the treatment of cancer. The company develops monoclonal antibodies with enhanced tumor cell-killing properties that target anti-Mullerian human receptors in ovarian cancer, enabling physicians to treat previously unaddressed targets in gynecological cancers.
Contact Information
Website
www.gamamabs.comCorporate Office
- Centre Pierre Potier, Oncopole entrée B
- 1 place Pierre Potier BP50624
- 31106 Toulouse
- France
Corporate Office
- Centre Pierre Potier, Oncopole entrée B
- 1 place Pierre Potier BP50624
- 31106 Toulouse
- France
GamaMabs Pharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Secondary Transaction - Private | 26-Mar-2026 | Completed | Startup | |||
| 7. Later Stage VC | 13-Sep-2021 | Completed | Startup | |||
| 6. Later Stage VC | 16-Jul-2020 | Completed | Startup | |||
| 5. Later Stage VC | 20-Jun-2018 | Completed | Startup | |||
| 4. Early Stage VC (Series B) | 15-Dec-2015 | Completed | Startup | |||
| 3. Early Stage VC | 03-Mar-2014 | Completed | Startup | |||
| 2. Early Stage VC (Series A) | 30-Sep-2013 | $4.81M | $4.81M | Completed | Startup | |
| 1. Accelerator/Incubator | Completed | Startup |
GamaMabs Pharma Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Shares C | ||||||||
| Shares B | ||||||||
| Shares P | 38,402 | $2.357795 | $110.52 | $110.52 | 1x | $110.52 | 13.35% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
GamaMabs Pharma Comparisons
Industry
Financing
Details
GamaMabs Pharma Competitors (20)
One of GamaMabs Pharma’s 20 competitors is Ability Pharma, a Private Equity-Backed company based in Cerdanyola, Spain.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Ability Pharma | Private Equity-Backed | Cerdanyola, Spain | ||||
| Biocon Biologics | Formerly PE-Backed | Bengaluru, India | ||||
| Gilead | Formerly VC-backed | Foster City, CA | ||||
| Genentech | Formerly VC-backed | South San Francisco, CA | ||||
| Ona Therapeutics | Venture Capital-Backed | Barcelona, Spain |
GamaMabs Pharma Patents
GamaMabs Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025248097-A2 | Humanized anti-human her3 antibodies and uses thereof | Pending | 31-May-2024 | ||
| WO-2025248097-A3 | Humanized anti-human her3 antibodies and uses thereof | Pending | 31-May-2024 | ||
| EP-3812008-A1 | Amh-competitive antagonist antibody | Inactive | 23-Oct-2019 | ||
| US-20230348607-A1 | Amh-competitive antagonist antibody | Inactive | 23-Oct-2019 | ||
| WO-2021078959-A1 | Amh-competitive antagonist antibody | Inactive | 23-Oct-2019 | C07K16/2869 |
GamaMabs Pharma Signals
GamaMabs Pharma Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Edmond de Rothschild Private Equity | PE/Buyout | Minority | ||
| Andera Partners | PE/Buyout | Minority | ||
| IRDI Capital Investissement | PE/Buyout | Minority | ||
| Alto Invest | Asset Manager | Minority | ||
| Bpifrance | Sovereign Wealth Fund | Minority |
GamaMabs Pharma FAQs
-
When was GamaMabs Pharma founded?
GamaMabs Pharma was founded in 2013.
-
Where is GamaMabs Pharma headquartered?
GamaMabs Pharma is headquartered in Toulouse, France.
-
What is the size of GamaMabs Pharma?
GamaMabs Pharma has 7 total employees.
-
What industry is GamaMabs Pharma in?
GamaMabs Pharma’s primary industry is Drug Discovery.
-
Is GamaMabs Pharma a private or public company?
GamaMabs Pharma is a Private company.
-
What is GamaMabs Pharma’s current revenue?
The current revenue for GamaMabs Pharma is .
-
How much funding has GamaMabs Pharma raised over time?
GamaMabs Pharma has raised $31.5M.
-
Who are GamaMabs Pharma’s investors?
Edmond de Rothschild Private Equity, Andera Partners, IRDI Capital Investissement, Alto Invest, and Bpifrance are 5 of 9 investors who have invested in GamaMabs Pharma.
-
Who are GamaMabs Pharma’s competitors?
Ability Pharma, Biocon Biologics, Gilead, Genentech, and Ona Therapeutics are some of the 20 competitors of GamaMabs Pharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process